Summit Therapeutics' ivonescimab outperforms Keytruda in NSCLC trial, driving share surge.
Summit Therapeutics' shares have surged nearly 900% this year, outpacing Nvidia's 137% increase, driven by the promising performance of ivonescimab in a phase 3 clinical trial for non-small cell lung cancer (NSCLC). The drug showed better results than Merck's Keytruda, the current standard of care. If approved in key markets, ivonescimab could significantly impact Keytruda's sales, potentially benefiting Summit's financial outlook. However, the investment remains risky.
September 22, 2024
4 Articles